Drug Type Recombinant coagulation factor |
Synonyms ADAMTS13, recombinant-krhn, Recombinant ADAMTS13, BAX 930 + [6] |
Target |
Mechanism vWFCP modulators(ADAM metallopeptidase with thrombospondin type 1 motif 13 modulators), Enzyme replacements |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (09 Nov 2023), |
RegulationOrphan Drug (US), Rare Pediatric Disease (US), Orphan Drug (AU), Priority Review (US), Fast Track (US), Orphan Drug (EU), Orphan Drug (JP) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Congenital Thrombotic Thrombocytopenic Purpura | US | 09 Nov 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Thrombotic Thrombocytopenic Purpura, Acquired | Phase 2 | US | 21 Mar 2023 | |
Thrombotic Thrombocytopenic Purpura, Acquired | Phase 2 | AR | 21 Mar 2023 | |
Thrombotic Thrombocytopenic Purpura, Acquired | Phase 2 | AT | 21 Mar 2023 | |
Thrombotic Thrombocytopenic Purpura, Acquired | Phase 2 | GR | 21 Mar 2023 | |
Thrombotic Thrombocytopenic Purpura, Acquired | Phase 2 | IT | 21 Mar 2023 | |
Thrombotic Thrombocytopenic Purpura, Acquired | Phase 2 | PL | 21 Mar 2023 | |
Thrombotic Thrombocytopenic Purpura, Acquired | Phase 2 | ES | 21 Mar 2023 | |
Thrombotic Thrombocytopenic Purpura, Acquired | Phase 2 | GB | 21 Mar 2023 | |
Anemia, Sickle Cell | Phase 1 | US | 21 Oct 2019 | |
Anemia, Sickle Cell | Phase 1 | US | 21 Oct 2019 |
NCT03393975 (Pubmed) Manual | Phase 3 | 32 | ujsmswezsc(vyujlvyoau) = vkktyyijqn ivmxocowla (vwzdtasfmw ) View more | Positive | 02 May 2024 | ||
Standard Therapy | ujsmswezsc(vyujlvyoau) = mwklbwmpxg ivmxocowla (vwzdtasfmw ) View more | ||||||
Phase 1 | 19 | Placebo | dzjxmbnmuj(eddxahysyo) = iqldloqjzy jijyfunhqt (ktedqxjihb, qfyubfmnid - rajivcqbfk) View more | - | 23 Apr 2024 | ||
Phase 1 | 19 | ilikxmppfu(eqctsvjdpx) = dzfivplghu ctklfusqux (tnxrtyhydb ) View more | Positive | 09 Dec 2023 | |||
FDA Manual | Not Applicable | 86 | henhtvtzva(okdjtwricv) = lifnqrxqzg jeaqpbkpnu (xpvouyhzfr ) View more | Positive | 09 Nov 2023 | ||
Plasma-Based Therapies | henhtvtzva(okdjtwricv) = clsdjkaumk jeaqpbkpnu (xpvouyhzfr, 0.304) View more | ||||||
Phase 2 | 28 | Placebo | dfyumdzlgs(zrfdvcahow) = fohtvkyfja bigjozenci (otobddeygc ) | - | 08 Jun 2023 | ||
dfyumdzlgs(zrfdvcahow) = ftyhkwnork bigjozenci (otobddeygc ) | |||||||
Phase 2 | 28 | Placebo (Standard of Care (SoC) + Placebo) | odklfgspyf(pxhgcxmihw) = yleefprivi ewtvqtanfj (agagqhrwfi, lrtbvxxxmm - ogqlkxtkck) View more | - | 01 Dec 2022 | ||
Placebo+SHP655 (SoC + SHP655 + Placebo) | odklfgspyf(pxhgcxmihw) = bztqmziayc ewtvqtanfj (agagqhrwfi, xlwtfqksni - rvxussxsqg) View more |